DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,745,873 | +0.1% | 192,446 | -3.2% | 0.13% | +3.2% |
| Q2 2023 | $47,706,740 | -49.2% | 198,778 | -46.7% | 0.13% | -45.7% |
| Q1 2023 | $93,909,852 | +89495.8% | 372,599 | -5.6% | 0.23% | -15.9% |
| Q4 2022 | $104,815 | -99.9% | 394,904 | -44.6% | 0.28% | -49.2% |
| Q3 2022 | $184,251,000 | -1.6% | 713,348 | -3.4% | 0.54% | +4.4% |
| Q2 2022 | $187,214,000 | -14.1% | 738,462 | -0.6% | 0.52% | -3.5% |
| Q1 2022 | $217,951,000 | -14.9% | 743,022 | -4.6% | 0.54% | -10.0% |
| Q4 2021 | $256,222,000 | +9.8% | 778,768 | +1.6% | 0.60% | +0.3% |
| Q3 2021 | $233,395,000 | +13.9% | 766,637 | +0.4% | 0.60% | +12.0% |
| Q2 2021 | $204,947,000 | +19.3% | 763,701 | +0.1% | 0.53% | +10.6% |
| Q1 2021 | $171,779,000 | -0.9% | 763,189 | -2.1% | 0.48% | -6.9% |
| Q4 2020 | $173,259,000 | -3.6% | 779,955 | -6.6% | 0.52% | -15.9% |
| Q3 2020 | $179,811,000 | +20.5% | 835,051 | -1.1% | 0.62% | +9.6% |
| Q2 2020 | $149,248,000 | +28.2% | 844,023 | +0.3% | 0.56% | +5.6% |
| Q1 2020 | $116,459,000 | -9.8% | 841,400 | +0.0% | 0.53% | +14.9% |
| Q4 2019 | $129,117,000 | +6.0% | 841,264 | -0.2% | 0.46% | -3.5% |
| Q3 2019 | $121,771,000 | +5.0% | 843,116 | +3.9% | 0.48% | +6.4% |
| Q2 2019 | $115,942,000 | +11.7% | 811,235 | +3.2% | 0.45% | -25.7% |
| Q1 2019 | $103,793,000 | +46.7% | 786,194 | +14.6% | 0.61% | +26.5% |
| Q4 2018 | $70,752,000 | +26.1% | 686,118 | +33.6% | 0.48% | +36.4% |
| Q3 2018 | $56,118,000 | +19.0% | 513,480 | +7.4% | 0.35% | +10.0% |
| Q2 2018 | $47,162,000 | +11.6% | 477,925 | +10.7% | 0.32% | +7.4% |
| Q1 2018 | $42,272,000 | +146.6% | 431,742 | +133.8% | 0.30% | +146.3% |
| Q4 2017 | $17,140,000 | +8.5% | 184,657 | +0.3% | 0.12% | +1.7% |
| Q3 2017 | $15,796,000 | +4.6% | 184,140 | +2.9% | 0.12% | +0.8% |
| Q2 2017 | $15,098,000 | +0.8% | 178,912 | +2.2% | 0.12% | -2.5% |
| Q1 2017 | $14,975,000 | +16.6% | 175,089 | +6.1% | 0.12% | +8.0% |
| Q4 2016 | $12,843,000 | -2.9% | 164,987 | -2.3% | 0.11% | -5.9% |
| Q3 2016 | $13,232,000 | -20.6% | 168,798 | -0.0% | 0.12% | -22.2% |
| Q2 2016 | $16,671,000 | +9.7% | 168,819 | +5.4% | 0.15% | +5.5% |
| Q1 2016 | $15,194,000 | -4.2% | 160,173 | -6.2% | 0.14% | -8.8% |
| Q4 2015 | $15,860,000 | +25.2% | 170,753 | +14.9% | 0.16% | +17.8% |
| Q3 2015 | $12,666,000 | +0.7% | 148,647 | +1.1% | 0.14% | +8.9% |
| Q2 2015 | $12,581,000 | – | 146,989 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |